Cite

    Benjamin Stolte et al.. “Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy.” Therapeutic advances in neurological disorders, vol. 11, 2018, p. . http://access.bl.uk/ark:/81055/vdc_100078219672.0x0000d5